Caiyutian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caiyutian Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hu Qiu
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
16 shared publications - Jiamei Chen
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
16 shared publications - Jing Wang
Department of Cancer Center, Renmin Hospital of Wuhan University, The first Clinical College of Wuhan University, Wuhan, China
16 shared publications - Shaobo Ke
College of Life Sciences & Renmin Hospital, Wuhan University, Wuhan, China
16 shared publications - Wei Shi
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
16 shared publications - Wenjie Zhang
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 5. Progression-free survival for patients received apatinib combined with tislelizumab and chemotherapy and underwent surgery (Blue) or no surgery (red).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 5. Progression-free survival for patients received apatinib combined with tislelizumab and chemotherapy and underwent surgery (Blue) or no surgery (red).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 1. Overall survival for patients received apatinib combined with tislelizumab and chemotherapy. The median overall survival reached 20.9 months (95% CI: 14.60–27.20).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 1. Overall survival for patients received apatinib combined with tislelizumab and chemotherapy. The median overall survival reached 20.9 months (95% CI: 14.60–27.20).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Trial Protocol, and Supplementary tables
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Trial Protocol, and Supplementary tables
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 3. Baseline systemic immunity markers (NLR, ALC, PLR, and LMR), blood biomarkers(CEA, CA199, CA72–4 and CA50) and lipid levels(TCH,TG, LDL-Ch and HDL-Ch) were not statistically associated with therapeutic response and PFS. NS = No significance; ALC = absolute lymphocyte count; NLC = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; LMR = lymphocyte-to-monocyte ratio; TCH = total cholesterol; TG = triglycerides; LDL-Ch = low density lipoprotein-cholesterol; HDL-Ch = high density lipoprotein-cholesterol; PR = partial response; SD = stable disease; PD = progressive disease; PFS = progression-free survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 3. Baseline systemic immunity markers (NLR, ALC, PLR, and LMR), blood biomarkers(CEA, CA199, CA72–4 and CA50) and lipid levels(TCH,TG, LDL-Ch and HDL-Ch) were not statistically associated with therapeutic response and PFS. NS = No significance; ALC = absolute lymphocyte count; NLC = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; LMR = lymphocyte-to-monocyte ratio; TCH = total cholesterol; TG = triglycerides; LDL-Ch = low density lipoprotein-cholesterol; HDL-Ch = high density lipoprotein-cholesterol; PR = partial response; SD = stable disease; PD = progressive disease; PFS = progression-free survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 2. Waterfall plot for tumor markers change is shown for 33 patients who had unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after receiving apatinib combined with tislelizumab and chemotherapy. Increase range more than 100% is considered as 100%.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 2. Waterfall plot for tumor markers change is shown for 33 patients who had unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after receiving apatinib combined with tislelizumab and chemotherapy. Increase range more than 100% is considered as 100%.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 4. Comparison of treatment effect between the two groups. Apatinib combined with tislelizumab and chemotherapy group (group 1), as compared with ICIs combined with chemotherapy group (group 2).CR = complete response; PR = partial response; PD = progressive disease; ORR = objective response rate; DCR = disease control rate.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 4. Comparison of treatment effect between the two groups. Apatinib combined with tislelizumab and chemotherapy group (group 1), as compared with ICIs combined with chemotherapy group (group 2).CR = complete response; PR = partial response; PD = progressive disease; ORR = objective response rate; DCR = disease control rate.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 6. Subscales of European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire per treatment cycle. The scores were divided by 100 for plotting. HRQoL = health-related quality of life. We used One-way ANOVA to compare quality-of-life data of different cycles, and we found that patients’ health-related quality of life improved after treatment. (P < 0.05).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 6. Subscales of European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire per treatment cycle. The scores were divided by 100 for plotting. HRQoL = health-related quality of life. We used One-way ANOVA to compare quality-of-life data of different cycles, and we found that patients’ health-related quality of life improved after treatment. (P < 0.05).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma with signet ring cell carcinoma or peritoneal metastasis were enrolled to receive eight cycles of apatinib, tislelizumab, and chemotherapy every 3 weeks, with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year. Homogeneous patients receiving immune checkpoint inhibitors combined with chemotherapy at the same time were deemed as the control group for efficacy. The primary endpoint was progression-free survival. Secondary endpoints were objective response rate, disease control rate, duration of response, overall survival, biomarkers, health-related quality of life, and safety. A total of 33 patients [median (range) age, 60 (32–72) years; 21 (63.6%) male; 11 (33.3%) signet ring cell carcinoma; 30 (90.9%) peritoneal metastasis] were enrolled and deemed evaluable for efficacy analysis. Of these patients, 32 (97%) were without disease progression, of whom 1 (3.0%) patient had complete response and 18 (54.6%) had partial response. Six patients (18.2%) were able to undergo surgery after treatment. After propensity score matching, the median progression-free survival was 10.17 months (95% confidence interval, 7.13–13.21) in the apatinib combined with tislelizumab and chemotherapy group, as compared with 6.0 months in the immune checkpoint inhibitor combined with chemotherapy group. The median duration of response increased from 4.5 to 8.7 months. The objective response rate increased from 33.3% to 54.6%, and the disease control rate increased from 87.9% to 97.0%. Treatment-related grade 3 or higher adverse events for evaluable patients occurred in 11 patients (33.3%), and patients’ health-related quality of life improved after treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma with signet ring cell carcinoma or peritoneal metastasis were enrolled to receive eight cycles of apatinib, tislelizumab, and chemotherapy every 3 weeks, with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year. Homogeneous patients receiving immune checkpoint inhibitors combined with chemotherapy at the same time were deemed as the control group for efficacy. The primary endpoint was progression-free survival. Secondary endpoints were objective response rate, disease control rate, duration of response, overall survival, biomarkers, health-related quality of life, and safety. A total of 33 patients [median (range) age, 60 (32–72) years; 21 (63.6%) male; 11 (33.3%) signet ring cell carcinoma; 30 (90.9%) peritoneal metastasis] were enrolled and deemed evaluable for efficacy analysis. Of these patients, 32 (97%) were without disease progression, of whom 1 (3.0%) patient had complete response and 18 (54.6%) had partial response. Six patients (18.2%) were able to undergo surgery after treatment. After propensity score matching, the median progression-free survival was 10.17 months (95% confidence interval, 7.13–13.21) in the apatinib combined with tislelizumab and chemotherapy group, as compared with 6.0 months in the immune checkpoint inhibitor combined with chemotherapy group. The median duration of response increased from 4.5 to 8.7 months. The objective response rate increased from 33.3% to 54.6%, and the disease control rate increased from 87.9% to 97.0%. Treatment-related grade 3 or higher adverse events for evaluable patients occurred in 11 patients (33.3%), and patients’ health-related quality of life improved after treatment.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Trial Protocol, and Supplementary tables
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Trial Protocol, and Supplementary tables
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 5. Progression-free survival for patients received apatinib combined with tislelizumab and chemotherapy and underwent surgery (Blue) or no surgery (red).
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 5. Progression-free survival for patients received apatinib combined with tislelizumab and chemotherapy and underwent surgery (Blue) or no surgery (red).